Probatebeta
Drug

Tedatioxetine

As of the edition of 20 October 2026, Tedatioxetine is a small molecule: went quiet in 2009; acts on ADRA1A, HTR2A and HTR2C and 8 more.

Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.

The drug

Status
Went quiet, 2009
Kind
Small molecule
Registered trials
1, 0 stopped early
Disease areas
Mental health

US protection

No US approval on record.

With no US approval on record there are no listed US patents or exclusivities.

This is the US only.

Companies that need a new molecule because of this drug

3 company-target rows on route B and 3 company-target rows on route A because of this drug.

Companies on route B for this drug

In the product

3 company-target rows are on route B because of Tedatioxetine.

See the 3 company-target rows on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.

Companies on route A for this drug

In the product

3 company-target rows are on route A because of Tedatioxetine.

See the 3 company-target rows on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.

Targets

GeneProteinUniProt
HTR3E5-hydroxytryptamine receptor 3EA5X5Y0
HTR3B5-hydroxytryptamine receptor 3BO95264
SLC6A2Sodium-dependent noradrenaline transporterP23975
HTR2A5-hydroxytryptamine receptor 2AP28223
HTR2C5-hydroxytryptamine receptor 2CP28335
SLC6A4Sodium-dependent serotonin transporterP31645
ADRA1AAlpha-1A adrenergic receptorP35348
HTR3A5-hydroxytryptamine receptor 3AP46098
SLC6A3Sodium-dependent dopamine transporterQ01959
HTR3D5-hydroxytryptamine receptor 3DQ70Z44
HTR3C5-hydroxytryptamine receptor 3CQ8WXA8

Registered trials

PhaseTrialsCompletedActiveStopped early
Phase 21100
All trials1

Who ran its trials

CompanyRoleYears
LundbeckLead sponsor of trials2007 to now

Other drugs at HTR3E

All of HTR3E